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Confined placental mosaicism (CPM) is defined as a chromosomally
abnormal cell line restricted to the placenta, while the fetus is chro-
mosomally normal. It was first described in 1983 in term placentae.
CPM can prenatally be detected by chorionic villus sampling (CVS) or
by noninvasive prenatal testing (NIPT) using cell-free (cf) DNA. NIPT
investigates DNA released from the cytotrophoblast (CTB) in maternal
blood plasma. CPM is now recognized as the major origin of discor-
dant NIPT results.
Little is known about the sensitivity of NIPT for detection of
CPM. Brison et al (2018) found evidence that NIPT is more sensitive
for the detection of placental mosaicism due to the observation of a
higher proportion of mosaicism for the common aneuploidies with
NIPT as compared to conventional karyotyping.1 In contrast, Benn
et al2 showed a significantly lower sensitivity for the detection of rare
autosomal aneuploidies (RATs), mostly involved in CPM, for NIPT
(0.32%) vs CVS (0.41%). The use of study cohorts with probably dif-
ferent a priori risk figures for CPM, may explain the conflicting results
of both studies. Moreover, whereas placental studies shed some light
on the correlation between cytogenetic results of CVS and those from
term placentae, little is known about how cytogenetic results of NIPT
relate to those from CVS and placenta. Papers on placental cytoge-
netic studies after NIPT are rare and amniocentesis is generally the
preferred technique for confirmatory diagnostic testing after an
abnormal NIPT result. Potential detection of chromosomal mosaicism
in CV, which may require an undesired second invasive procedure for
clarification of the fetal karyotype, may discredit CVS. However, if
both cell layers of CV (CTB and mesenchymal core [MC]) are investi-
gated separately, thus enabling differentiation between their respec-
tive chromosomal constitution, the risk of a confirmatory
amniocentesis after CVS is predicted to be low for the common triso-
mies (eg, trisomy 21 (2%), trisomy 18 (4%), and trisomy 13 (8%-
22%)3,4). On the contrary, if NIPT indicates another trisomy, CPM is
the most likely reason for this result. In such cases CVS for confirma-
tion is only recommended for RATs that are mostly involved in CPM
type 1, like trisomy 3, 7, 8, 9, 20.3 In all other cases, amniocentesis is
indeed the preferred confirmatory test. Hence little is known about
the representation of the placental chromosomal constitution in the
cfDNA fraction in cases of CPM and about the sensitivity of NIPT to
detect it. It is assumed that the entire placental trophoblast sheds
cfDNA into the maternal circulation and that a CPM restricted to
smaller placental areas may be detected by NIPT and missed by CVS.1
However, as far as we know, there are no studies comparing NIPT,
CVS and placenta cytogenetic data. Based on four cases with normal
CVS results after genome-wide (gw) NIPT revealed a RAT, we show
evidence that NIPT is better able to detect (low-level) placental mosai-
cism involving the cytotrophoblast than CVS.
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Genome-wide NIPT was performed as part of the Dutch Trident 2
study (Trident = Trial by Dutch laboratories for Evaluation of NIPT),
using shallow massively parallel sequencing and WISECONDOR for
analysis.5 The four cases presented here involved one case of trisomy
5 and trisomy 7 and three cases of trisomy 8. According to our local
protocol, a CVS was recommended, which was performed tra-
nsabdominally in all cases. Cytogenetic investigations of first trimester
CV were performed with SNP array (Illumina Infinium GSA + MD-24
v1.0 BeadChip genotyping array) on DNA isolated from the CTB and
MC that were separated as described previously.6 Maternal genomic
DNA was investigated as well to exclude a maternal origin of the chro-
mosomal aberration. In all four cases, a normal result was achieved in
CV (both CTB and MC) and maternal blood. The test characteristics of
NIPT (gestational age (GA), fetal fraction (FF) (SeqFF)7 and z-score
(chromosome-wide aneuploidy test [CWAT]8) and CVS (GA and
amount of CV) are shown in Table 1. Since maternal genomic DNA
was normal in all cases, a diagnosis of CPM was most likely, despite
normal CV results. After birth, we collected the placentae and per-
formed cytogenetic analysis of four CV biopsies from four quadrants,
with methods described for first trimester CV (Table 1). In all cases, the
chromosomal aberration was confirmed in the term placenta. In two
cases, it was present only in one of four biopsies, involving a 100% tri-
somy 5 and trisomy 7 in case 1 (Figure 1), but a very low level mosaic
in case 2. The presence of only 10% abnormal cells in one biopsy in
case 2 was sufficient to lead to an abnormal NIPT-result. However,
sampling of only 4 × 1 cm3 biopsies does not exclude higher levels of
trisomic cells elsewhere in the placenta. In cases 3 and 4, a 100% tri-
somy was present in two of the four biopsies, while first trimester CV
showed normal results, confirming the nonrepresentativity of first tri-
mester CV for the placenta as a whole, as illustrated in the past. Our
study shows a higher sensitivity of NIPT for detection of CPM involv-
ing the cytotrophoblast as compared to CVS.
A striking observation is that whereas the results in placental
studies of cases 3 and 4 were comparable, z-scores of the NIPT were
much higher in case 4 (32.6) as compared to case 3 (9.5). This may be
partly due to a higher FF (11.6% in case 4 vs 7.5% in case 3), however,
other factors may be involved that can explain this difference. Firstly,
only 4 biopsies of 1 cm3 were investigated leaving the largest part of
the placenta uninvestigated, which may contain much higher levels of
trisomic cells in case 4 as compared to case 3. Secondly, it is also pos-
sible that apoptotic activity in the affected placental parts in case 4 is
much higher than in case 3, leading to a higher trisomic cfDNA frac-
tion. In order to get more insight into the representativeness of NIPT
for the placenta anomaly, further studies are necessary and preferably
should involve more than four placental biopsies.
In three of the four cases, all involving CPM type 1 with the chro-
mosome aberration restricted to the CTB, children without congenital
anomalies and with appropriate birth weights were born, as can be
expected for this CPM type. Clinical outcome data are shown in
Table 1. In case 3 with the chromosome aberration present in both
cell layers, a premature delivery due to a rupture of membranes
occurred at 20 1/7 weeks. Unfortunately, no cord blood could be
obtained and therefore, a fetal trisomy 8 could not be excluded.
CPM is associated with an increased risk for preterm birth, small
for gestational age newborns, and adverse pregnancy outcomes.9 This
association especially exists for CPM type 3, mostly of meiotic origin,
in which both CTB and MC of first trimester CV are affected, often
with high percentages of abnormal cells, and less for CPM type 1 (only
CTB affected) and type 2 (only MC affected).9 Discrimination of the
various types of CPM is only possible when both the CTB and MC of
CV are investigated. When both cell layers are affected with high
levels of abnormal cells, while the fetus is chromosomally normal,
proper clinical follow-up investigations like expert ultrasound can be
recommended. However, if potential CPM is detected with NIPT, no
differentiation between CPM type 1 and 3 is possible since only the
CTB is investigated with NIPT. Also, little is known about the extent
of the distribution of abnormal cells over the placenta when NIPT
reveals CPM. Moreover, as shown in this paper, NIPT seems to be
very sensitive for detection of CPM, even if restricted to a small area
of the placenta, with probably less clinical consequences. This all com-
plicates predictions on the clinical relevance of CPM when detected
with NIPT. Further research is necessary in order to learn to differen-
tiate clinically relevant CPM from benign CPM. Recently, Pertile et al
(2017) and Brison et al (2018) found an association between trisomic
fraction and pregnancy outcome. When a trisomic fraction as com-
pared to fetal fraction was low, pregnancy outcome was favorable
and if trisomic fraction was high there was an increased risk for
adverse outcome such as miscarriage, intrauterine fetal death, intra-
uterine growth retardation1,10 This shows that the trisomic fraction
may be a good indicator for aneuploidy-load in the placenta, and its
calculation probably may improve clinical guidance of the pregnancy.1
In conclusion, the present study shows that NIPT seems to be
more sensitive than CVS for the detection of CPM involving the cyto-
trophoblast. However, the ability of NIPT to detect a low level mosaic
restricted to a small placental part will probably be dependent on the
FF. This study also gives more insight into the representation of CPM
in the cfDNA fraction of maternal blood. However, more studies are
What's already known about this topic?
• Confined placental mosaicism (CPM) can prenatally be
detected with chorionic villus sampling (CVS) and nonin-
vasive prenatal testing (NIPT).
• Chromosomally abnormal cells may be restricted to a
small part of the placenta.
• The level of mosaicism detected by CVS does not always
reflect the level present in the term placenta.
What does this study add?
• NIPT as compared to CVS is more sensitive for detection
of CPM involving the cytotrophoblast that is restricted to
a (small) part of the placenta.
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F IGURE 1 NIPT and array results in case 1. A, WISECONDOR plot showing the abnormal NIPT result in case 1 with a trisomy of both
chromosomes 5 and 7. B and C, array result of the cytotrophoblast of placental biopsy 3. B, shows the whole genome LogR and C, the whole
genome B-allele frequency (BAF). Both reveal a nonmosaic trisomy 5 and trisomy 7 in the presence of approximately 10% maternal cell
contamination. The latter can be seen in the BAF profile at a BAF of 0 and 1.0 (arrows). The differences in the BAF-profiles of chromosomes
5 and 7 are caused by a different parental origin of both trisomies, with trisomy 5 having a maternal and trisomy 7 a paternal origin [Colour figure
can be viewed at wileyonlinelibrary.com]
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necessary to understand the correlation between NIPT z-scores/triso-
mic fraction and level and distribution of mosaicism in the placenta in
order to learn to predict the clinical consequences of CPM, when
detected with NIPT.
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